Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
1972-1-11
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0014-4754
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1048-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:5116129-Brain,
pubmed-meshheading:5116129-Brain Chemistry,
pubmed-meshheading:5116129-Dihydroxyphenylalanine,
pubmed-meshheading:5116129-Dopamine,
pubmed-meshheading:5116129-Humans,
pubmed-meshheading:5116129-Methyldopa,
pubmed-meshheading:5116129-Parkinson Disease,
pubmed-meshheading:5116129-Phenylacetates
|
| pubmed:year |
1971
|
| pubmed:articleTitle |
L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions.
|
| pubmed:publicationType |
Journal Article
|